The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.

Cancers (Basel) · 2017 · PMC5615336 · PMID 28891959

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The highly significant difference in CFUs recovered from the bone marrow of mice in the two groups ( Figure 5 ) implies that the pretreatment with idelalisib affects the ability of these ALL cells to home to the bone marrow.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.